Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes
- PMID: 36811241
- DOI: 10.1002/oby.23677
Glucagon-like peptide-1 agonists combined with sodium-glucose cotransporter-2 inhibitors reduce weight in type 1 diabetes
Abstract
Objective: This study evaluated whether adding sodium-glucose cotransporter-2 inhibitors (SGLT2i) and/or glucagon-like peptide-1 receptor agonists (GLP1-RA) to insulin reduced weight and glycemia in people with type 1 diabetes.
Methods: This retrospective analysis of electronic health records evaluated 296 people with type 1 diabetes over 12 months after medications were first prescribed. Four groups were defined: control n = 80, SGLT2i n = 94, GLP1-RA n = 82, and combination of drugs (Combo) n = 40. We measured changes at 1 year in weight and glycated hemoglobin (HbA1c).
Results: The control group did not have changes in weight or glycemic control. The mean (SD) percentage weight loss after 12 months was 4.4% (6.0%), 8.2% (8.5%), and 9.0% (8.4%) in the SGLT2i, GLP1-RA, and Combo groups, respectively (p < 0.001). The Combo group lost the most weight (p < 0.001). The HbA1c reduction was 0.4% (0.7%), 0.3% (0.7%), and 0.6% (0.8%) in the SGLT2i, GLP1-RA, and Combo groups, respectively (p < 0.001). The Combo group had the biggest improvements in glycemic control and total and low-density lipoprotein cholesterol compared with baseline (all p < 0.01). Severe adverse events were similar between all the groups, with no increased risk of diabetic ketoacidosis.
Conclusions: The SGLT2i and GLP1-RA agents on their own improved body weight and glycemia, but combining the medications resulted in more weight loss. Treatment intensification appears to result in benefits with no difference in severe adverse events.
© 2023 The Authors. Obesity published by Wiley Periodicals LLC on behalf of The Obesity Society.
Similar articles
-
Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus.Circulation. 2019 Apr 23;139(17):2022-2031. doi: 10.1161/CIRCULATIONAHA.118.038868. Circulation. 2019. PMID: 30786725
-
The prescribing pattern of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in patient with type two diabetes mellitus: A two-center retrospective cross-sectional study.Front Public Health. 2022 Oct 28;10:1031306. doi: 10.3389/fpubh.2022.1031306. eCollection 2022. Front Public Health. 2022. PMID: 36408008 Free PMC article.
-
Real-world effectiveness and safety of dapagliflozin therapy added to a GLP1 receptor agonist in patients with type 2 diabetes.Nutr Metab Cardiovasc Dis. 2017 Feb;27(2):129-137. doi: 10.1016/j.numecd.2016.11.007. Epub 2016 Nov 23. Nutr Metab Cardiovasc Dis. 2017. PMID: 28077257
-
Combination of SGLT-2 Inhibitors and GLP-1 Receptor Agonists: Potential Benefits in Surrogate and Hard Endpoints.Curr Pharm Des. 2018;24(17):1879-1886. doi: 10.2174/1381612824666180604113653. Curr Pharm Des. 2018. PMID: 29865997 Review.
-
A review of glucagon-like peptide 1 receptor agonist and sodium-glucose cotransporter 2 inhibitor cardiovascular trials: Implications for practice.J Am Assoc Nurse Pract. 2021 Mar 4;33(12):1139-1147. doi: 10.1097/JXX.0000000000000516. J Am Assoc Nurse Pract. 2021. PMID: 33105320 Review.
References
REFERENCES
-
- DiMeglio LA, Evans-Molina C, Oram RA. Type 1 diabetes. Lancet. 2018;391:2449-2462.
-
- Nathan DM, Cleary PA, Backlund J-YC, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 2005;353:2643-2653.
-
- Malkani S, Kotwal A. Frequency and predictors of self-reported hypoglycemia in insulin-treated diabetes. J Diabetes Res. 2017;2017:7425925. doi:10.1155/2017/7425925
-
- McCall AL, Farhy LS. Treating type 1 diabetes: from strategies for insulin delivery to dual hormonal control. Minerva Endocrinol. 2013;38:145-163.
-
- Russell-Jones D, Khan R. Insulin-associated weight gain in diabetes--causes, effects and coping strategies. Diabetes Obes Metab. 2007;9:799-812.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical